Skip to main content
Print Save

Vyepti Side Effects

Generic name: eptinezumab

Medically reviewed by Philip Thornton, DipPharm. Last updated on Nov 10, 2022.

Note: This document contains side effect information about eptinezumab. Some dosage forms listed on this page may not apply to the brand name Vyepti.

Applies to eptinezumab: intravenous solution.

Serious side effects of Vyepti

Along with its needed effects, eptinezumab (the active ingredient contained in Vyepti) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking eptinezumab:

Less common

  • Chest tightness
  • fast heartbeat
  • feeling of warmth
  • fever
  • hives, itching, skin rash
  • hoarseness
  • irritation
  • joint pain, stiffness or swelling
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, sex organs
  • redness of the skin
  • redness of the face, neck, arms and occasionally, upper chest
  • swelling of the eyelids, face, lips, hands, or feet
  • trouble breathing or swallowing

Incidence not known

  • Cough
  • dizziness
  • unusual tiredness or weakness

Other side effects of Vyepti

Some side effects of eptinezumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Headache
  • muscle aches
  • sore throat
  • stuffy or runny nose

Incidence not known

  • Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site

For Healthcare Professionals

Applies to eptinezumab: intravenous solution.

General

The most commonly reported adverse reactions were nasopharyngitis and hypersensitivity.[Ref]

Hypersensitivity

Common (1% to 10%): Hypersensitivity (including angioedema, urticaria, flushing, rash

and pruritus)

Postmarketing reports: Anaphylactic reactions (including hypotension and respiratory difficulties)

Immunologic

Very common (10% or more): Anti-drug antibodies (up to 20.6%)

Local

Uncommon (less than 2%): Infusion-site reactions including extravasation

Other

Common (1% to 10%): Fatigue

Respiratory

Common (1% to 10%): Nasopharyngitis

Frequency not reported (infusion-related respiratory symptoms): Nasal congestion, rhinorrhea, throat irritation, cough, sneezing, dyspnea

Frequently asked questions

References

1. Product Information. Vyepti (eptinezumab). Lundbeck Inc. 2022.

2. Product Information. Vyepti (eptinezumab). Lundbeck Ltd. 2022.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer